View Cart   •   Checkout   •   Register   •   Login  
 


Click here to view larger image

Osatate
(Calcium Hydroxyapatite)
Price: $21.00 
100 capsules

Mail E-mail this product to a friend



Quantity:  

Benefits of taking Ostate (Calcium Hydroxyapatite)

Most people have either heard or read about the importance of calcium. It is likely that calcium is perhaps the most well known and most commonly taken supplements. In fact, as a society we may actually over-emphasize calcium. This topic is discussed in more detail in the osteoporosis section. The main point to appreciate here is that a calcium supplement is not a magic bullet. Calcium needs to considered in the context of diet and other supplements.

As you read in the magnesium supplement section, nearly all adult Americans are likely to be deficient in magnesium and vitamin D. This means that supplementation with calcium without magnesium and vitamin D is not the best choice we can make. All three should be taken.

At deflame.com, we offer Osatate, which is a microcrystalline hydroxyapatite (MCHC) supplement. MCHC is derived from whole bone and contains an organic and inorganic component. The organic component consists of collagen, glycosaminoglycans, peptides, and growth factors for bone. The inorganic component contains predominately calcium and phosphorus. Research suggests that MCHC is the best source for calcium to help maintain normal bone density (1-4).

 

References
1. Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound (dOssopanT) in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin 1984;8:734-42.
2. Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J 1985;61:791-6.
3. Ruegsegger P, Keller A, Dambacher MA. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporosis Int 1995;5:30-4
4. Castelo-Branco C, Pons F, Vicente JJ, Sanjuan A, Vanrell JA. Preventing postmenopausal bone loss with ossein-hydroxyapatite compounds. Results of a two-year prospective trial. J Reprod Med. 1999; 44(7):601-5

Disclaimer

HOME • INFLAMMATION • INFLAMMATORY DISEASES • WELLNESS • DIET • SUPPLEMENTS • SUPPLEMENT QUALITY
SUCCESS STORIES • Q & A • NEW RESEARCH • STORE • FOR DOCTORS • FOR CORPORATIONS • CONTACT US • NEWSLETTER SIGNUP